Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor
Introducing a new therapeutic approach for patients with movement disorders
Cavion, Inc. announced today that the first patient has been enrolled in its new T-CALM Study (Tremor Cav3 Modulation Study), a Phase 2 clinical trial using the company’s T-type calcium channel modulator CX-8998 for patients with Essential Tremor (ET).